Supplementary Figure 1: Equilibrium binding analyses of the interaction of efgartigimod with human FcRn

Similar documents
Supplementary Figure 1. Characterization of human carotid plaques. (a) Flash-frozen human plaques were separated into vulnerable (V) and stable (S),

Supplementary Figures

Supplementary Figure 1. ALVAC-protein vaccines and macaque immunization. (A) Maximum likelihood

Crystallization-grade After D After V3 cocktail. Time (s) Time (s) Time (s) Time (s) Time (s) Time (s)

Table of Contents. Plots. Essential Statistics for Nursing Research 1/12/2017

IgG3 regulates tissue-like memory B cells in HIV-infected individuals

pro-b large pre-b small pre-b CCCP (µm) Rag1 -/- ;33.C9HCki

Supplementary Figure 1. BMS enhances human T cell activation in vitro in a

Supplementary figures and tables. Figure A: Study schematic

Supplementary Figure 1. Characterization of basophils after reconstitution of SCID mice

Kevin Fitzgerald, PhD

d e f Spatiotemporal quantification of subcellular ATP levels in a single HeLa cell during changes in morphology Supplementary Information

genome edited transient transfection, CMV promoter

a surface permeabilized

Nature Neuroscience: doi: /nn Supplementary Figure 1

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

PROGRAMMER S SAFETY KIT: Important Points to Remember While Programming or Validating Safety Tables

B220 CD4 CD8. Figure 1. Confocal Image of Sensitized HLN. Representative image of a sensitized HLN

SUPPLEMENTARY INFORMATION

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

Nature Medicine: doi: /nm.4078

Study No Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Study Endpoints: Pharmacokinetics:

Generation of ST2-GFP reporter mice and characterization of ILC1 cells following infection

Combined Rho-kinase inhibition and immunogenic cell death triggers and propagates immunity against cancer

Treatment A Placebo to match COREG CR 20 mg OD + Lisinopril 10 mg OD (Days 1-7) Placebo to match COREG CR 40 mg OD + Lisinopril 10 mg OD (Days 8-14)

Supplementary Figure 1. Using DNA barcode-labeled MHC multimers to generate TCR fingerprints

Study Centers: This study was conducted in 2 centers in Italy.

Figure S1. Western blot analysis of clathrin RNA interference in human DCs Human immature DCs were transfected with 100 nm Clathrin SMARTpool or

Pearson r = P (one-tailed) = n = 9

PKMζ maintains memories by regulating GluR2- dependent AMPA receptor trafficking

LPS CD40 + IL-4. Vorinostat (24 Hours) Vorinostat (24 Hours) Panobinostat (24 Hours) Panobinostat (24 Hours) Romidepsin (48 Hours)

Cohort 2. Age, years 41.0 (10.2) Diabetes duration, years 26.5 (15.8)

Supplementary Figure 1. Properties of various IZUMO1 monoclonal antibodies and behavior of SPACA6. (a) (b) (c) (d) (e) (f) (g) .

PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.

Chronic variable stress activates hematopoietic stem cells

a b c Esophageal eosinophilia

a 10 4 Link et al. Supplementary Figure 1 Nature Immunology: doi: /ni.1842 Cells per mouse ( 10 5 ) TRPV2KO anti-gr1 anti-gr anti-f4/80

ALN-PCSsc, an RNAi Investigational Agent That Inhibits PCSK9 Synthesis With the Potential for Effective Bi-Annual Dosing: Interim Results

Figure S1: Effects on haptotaxis are independent of effects on cell velocity A)

Supplementary Figure 1. SybII and Ceb are sorted to distinct vesicle populations in astrocytes. Nature Neuroscience: doi: /nn.

Supplementary Figure 1 Information on transgenic mouse models and their recording and optogenetic equipment. (a) 108 (b-c) (d) (e) (f) (g)

Nature Neuroscience: doi: /nn Supplementary Figure 1. Behavioral training.

Supplementary Information

SUPPLEMENTARY MATERIALS

Nature Neuroscience: doi: /nn Supplementary Figure 1

Schwarz et al. Activity-Dependent Ubiquitination of GluA1 Mediates a Distinct AMPAR Endocytosis

Types of Statistics. Censored data. Files for today (June 27) Lecture and Homework INTRODUCTION TO BIOSTATISTICS. Today s Outline

PRINCIPLES OF STATISTICS

These results are supplied for informational purposes only.

Supplementary Materials for

Quantification of intracellular payload release from

Support for Acetaminophen 1000 mg Over-the-Counter Dose:

Supplementary Figure 1. SDS-FRL localization of CB 1 in the distal CA3 area of the rat hippocampus. (a-d) Axon terminals (t) in stratum pyramidale

Polyclonal Secondary Antibodies

Supplementary Figure 1 Protease allergens induce IgE and IgG1 production. (a-c)

SYNOPSIS. Publications No publications at the time of writing this report.

Choosing the Correct Statistical Test

Full Novartis CTRD Results Template

UI α (n=150) Mean (SD) or N (%)

% of live splenocytes. STAT5 deletion. (open shapes) % ROSA + % floxed

B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction

SUPPLEMENTARY INFORMATION

Math Workshop On-Line Tutorial Judi Manola Paul Catalano. Slide 1. Slide 3

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

Market Access CTR Summary

Supplementary Materials

Supplementary Figure 1: Expression of NFAT proteins in Nfat2-deleted B cells (a+b) Protein expression of NFAT2 (a) and NFAT1 (b) in isolated splenic

Supplementary Figure 1. Double-staining immunofluorescence analysis of invasive colon and breast cancers. Specimens from invasive ductal breast

STATISTICS AND RESEARCH DESIGN

Two distinct mechanisms for experiencedependent

Product: Denosumab (AMG 162) Clinical Study Report: month Primary Analysis Date: 21 November 2016 Page 1

Math Workshop On-Line Tutorial Judi Manola Paul Catalano

Supporting Information Table of Contents

Title: Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations

Rachael E. Jack, Caroline Blais, Christoph Scheepers, Philippe G. Schyns, and Roberto Caldara

Product: Omecamtiv Mecarbil Clinical Study Report: Date: 02 April 2014 Page 1

Supplemental Information. A Visual-Cue-Dependent Memory Circuit. for Place Navigation

Appendix Figure S1 A B C D E F G H

COPD lungs show an attached stratified mucus layer that separate. bacteria from the epithelial cells resembling the protective colonic

Nature Immunology: doi: /ni.3631

Supplemental Figure 1. Gating strategies for flow cytometry and intracellular cytokinestaining

Which Hospitals Treat Patients with the Most Severe Acute Ischemic Strokes? Implications for Hospital Mortality Reporting

Nature Protocols: doi: /nprot Supplementary Figure 1

Supplementary Figure 1) GABAergic enhancement by leptin hyperpolarizes POMC neurons A) Representative recording samples showing the membrane

Supplemental Information. Checkpoint Blockade Immunotherapy. Induces Dynamic Changes. in PD-1 CD8 + Tumor-Infiltrating T Cells

Varun Goel 1, Nathalie H Gosselin 2, Claudia Jomphe 2, Husain Attarwala 1, Xiaoping (Amy) Zhang 1, JF Marier 2, Gabriel Robbie 1

Phenotype Determines Nanoparticle Uptake by Human

HD1 (FLU) HD2 (EBV) HD2 (FLU)

One way Analysis of Variance (ANOVA)

SUPPLEMENTARY INFORMATION

Supplementary information Common molecular mechanism of amyloid pore formation by Alzheimer s -amyloid peptide and -synuclein

D CD8 T cell number (x10 6 )

Nature Immunology: doi: /ni Supplementary Figure 1

Supplementary Figure 1. Enhanced detection of CTLA-4 on the surface of HIV-specific

Nature Neuroscience: doi: /nn Supplementary Figure 1. Large-scale calcium imaging in vivo.

Supplementary Figure 1: Kv7 currents in neonatal CA1 neurons measured with the classic M- current voltage-clamp protocol.

Supplementary Materials

Control GST GST-RAP. α2-mg. 170 kda. b-actin. 42 kda LRP-1

Post- Selection Purity Spleen VAT Spleen <B576/26-A>: B220

Transcription:

SULEMENTARY DATA Supplementary Figure 1: Equilibrium binding analyses of the interaction of with human FcRn using SR. The coupling density of was 275 RU. Human FcRn was injected over the flow cells at concentrations ranging from.1-1.33 mm (ph 6.) or.1-2.67 mm (ph 7.4) in BS (ph 6. or ph 7.4),.5% Tween at a flow rate of ml/min. Representative sensorgrams for duplicate or triplicate injections for each concentration are shown. Sensorgrams were zero-adjusted and reference cell data subtracted. Supplementary Figure 2: Equilibrium binding analyses of the interaction of the anti-fcrn antibody with human FcRn using SR. The coupling density of anti-fcrn antibody was 1552 RU. Human FcRn was injected over the flow cells at concentrations ranging from.7-178 (ph 6.) or.7-178 nm (ph 7.4) in BS (ph 6. or ph 7.4),.5% Tween at a flow rate of 5 ml/min. Representative sensorgrams for duplicate or triplicate injections for each concentration are shown. Sensorgrams were zero-adjusted and reference cell data subtracted. 1

Supplementary Figure 3: Subcellular trafficking behavior of. HMEC-1 cells expressing human FcRn-GF were pulse-chased with 5 μg/ml Alexa 555-labeled dextran to label lysosomes, and then pulse-chased (3 minutes pulse, 16 hours chase) with Alexa 647-labeled ( μg/ml). A, the intensity of the Alexa 647 channel was piecewise linearly adjusted. White arrowheads in the images indicate the localization of in dextran-positive lysosomes. GF, Alexa 555, and Alexa 647 are pseudocolored blue, red, and green, respectively. Bar = 3 μm. B,C, pixel intensities for the Alexa 647 fluorescence across the indicated line on the image without any adjustment (B; raw intensity, used for data shown in Figure 2C), or with piecewise linear adjustment (C) for the image shown in A. Consistent with the piecewise linear adjustment of the image shown in A, the pixel traces have the same profiles but the intensities are piecewise linearly offset from each other. 2

Supplementary Figure 4: Cross-species FcRn binding. Binding of or an unmodified Fc fragment (wt-fc) to human or cynomolgus monkey FcRn binding at both acidic (A) and neutral ph (B) as measured by ELISA. Representative data for at least 3 experiments are shown. A B Supplementary Figure 5: Efgartigimod does not alter IgA nor IgM levels in cynomolgus monkeys. Animals (n = 2/group) were injected with 1 mg/kg of the non-target-binding human IgG1 tracer antibody FR7-hIgG1, followed 2 days later with an i.v. infusion of 2 mg/kg or vehicle. ciga (A) and cigm (B) levels in serum, determined using a commercial ELISA kit, were plotted relative to pre-dose levels (percent change from baseline; %T ). Values are mean ± S.E.M. 3

Supplementary Figure 6: Serum levels of IgA, IgD, IgE, IgM, and albumin over time in the MAD part of the first-in-human study. Healthy subjects (n = 8) were dosed with mg/kg or placebo on four occasions (Cohort ). or placebo (randomized in a 6:2 ratio) was administered i.v. in a 2-hour infusion. ercent change versus baseline in IgA, IgD, IgE, IgM, and albumin serum concentration (%T ) is shown; values are mean ± SD. * Two subjects in the active group and 1 subject in the placebo group had IgD values below limit of quantification during the whole study period. 4

Supplementary Table 1: Mean fluorescence intensity values for flow cytometry experiments. Mean fluorescence intensities (MFIs, Duplicate values for each time point) obtained from two flow cytometric analyses of cell-associated fluorescence for HMEC-1 cells following pulse-chase treatment with fluorescently labeled antibodies/antibody Fc fragments. Chase time Experiment 1 (MFI)* Experiment 2 (MFI)* 9.4 5 8.2 5 1.5 6 1.4 6 Efgartigimod 3 4.3 5 3.6 5 4.6 5 5. 5 12 2.4 5 2.1 5 5 2.2 5 3.4 4 2.2 4 3.4 4 2.7 4 Human IgG1 3 5.5 3 7.4 3 7.1 3 5.4 3 12 7.4 3 4.7 3 5.1 3 6.2 3 1.3 6 1.2 6 1.9 6 6 Anti-FcRn 3 1.2 6 1.3 6 1.9 6 1.9 6 12 1.5 6 1.4 6 1.7 6 1.7 6 *Duplicate values for each time point. 5

Supplementary Table 2: Summary D parameters (SAD part of the first-in-human study). Healthy subjects (n = 6/group) were dosed with, 2,,, or 5 mg/kg or placebo (i.e., Cohort 1-5). or placebo (randomized in a 4:2 ratio) was administered i.v. in a 2-hour infusion. Values are arithmetic mean except median (min-max) for t Emax. AUEC and E max were compared between the treatment groups (placebo subjects pooled) using a one-way ANOVA model with treatment as fixed effect. In case of a significant treatment effect (p<.5), pairwise comparison between treatments was performed using Tukey s test. For t Emax comparison between treatment groups was assessed by using a non-parametric Kruskal-Wallis test and, in case statistically significant (p<.5), by applying Wilcoxon s rank sum test with Moses 9% CIs for pairwise comparisons. D arameter ooled lacebo N= mg/kg mg/kg mg/kg mg/kg 5 mg/kg ANOVA (p-value) Tukey s test a IgG1 Emax (%) -9.77-7.4-21.8-49.1-54.3-58.3 AUEC (%*h) 82-12.7-943 -269-297 -32 3. (-671.7) 12.1 (.-54.) 335.8 (144.-336.4) 335.8 (332.9-336.) 335.7 (335.6-336.7) 336. (336.-336.1) 5 5.347 5 6

D arameter ooled lacebo N= mg/kg mg/kg mg/kg IgG2 mg/kg 5 mg/kg ANOVA (p-value) Tukey s test a Emax (%) -14.2-13.5-19.6-43.5-42.4-52.3 AUEC (%*h) -197-415 -539-23 -222-284 49. (-671.7) 12.1 (4.-336.) 216.2 (96.-336.4) 334.3 (143.9-54.3) 53.9 (53.8-54.1) 54. (336.-54.) Emax (%) -8.35-6. -24. -54. -56.2-61.1 AUEC (%*h) 312 1658-797 -269-276 -32 (.-143.7) 12.1 (.-54.) 12. (96.-144.) IgG3 143.8 (96.-144.1) 144. (96.1-335.6) 144.2 (144.-336.1) 5 5.971 5 5.4 5 7

D arameter ooled lacebo N= mg/kg mg/kg mg/kg mg/kg 5 mg/kg ANOVA (p-value) Tukey s test a IgG4 Emax (%) -.5-9.92-16.1-36.6-42.3-46. AUEC (%*h) 812-116 -573-189 -122-4. (-671.7) 144.1 (4.-54.) 335.8 (144.-336.4) 238.4 (143.8-335.9) 335.6 (72.1-54.1) 336. (336.-336.1) 5.1 5 N, number of subjects. a Tukey s test: means are sorted in descending order, black: doses statistically different, gray: doses not statistically different; Kruskal-Wallis and Wilcoxon s rank sum test for temax 453 8

Supplementary Table 3: Summary D parameters (MAD part of the first-in-human study). Healthy subjects (n = 8/group) were dosed with mg/kg or placebo on six occasions (Cohort 7), mg/kg or placebo on four occasions (Cohort 9), or mg/kg or placebo on four occasions (Cohort ). or placebo (randomized in a 6:2 ratio) was administered i.v. in a 2-hour infusion. Values are arithmetic mean except median (min-max) for t Emax. AUEC and E max were compared between the treatment groups (placebo subjects pooled) using a one-way ANOVA model with treatment as fixed effect. In case of a significant treatment effect (p<.5), pairwise comparison between treatments was performed using Tukey s test. For t Emax comparison between treatment groups was assessed by using a non-parametric Kruskal-Wallis test and, in case statistically significant (p<.5), by applying Wilcoxon s rank sum test with Moses 9% CIs for pairwise comparisons. D arameter ooled lacebo mg/kg N=5 mg/kg mg/kg a ANOVA (p-value) Tukey s test b IgG1 Emax (%) -8.32-78.5-73. -77.7 AUEC (%*h) 1552-757 -65-917 3 (.-1824) 576. (48-696.) 576. (55-648.2) 624.2 (456.-648.6).3713 9

D arameter ooled lacebo mg/kg N=5 mg/kg IgG2 mg/kg a ANOVA (p-value) Tukey s test b Emax (%) -8.58-74.9-64.6-76.8 AUEC (%*h) 2445-852 -568-97. 576. 576. 624.5 (.-1849) (48-624.) (48.-648.2) (576.-648.5) IgG3 Emax (%) -11.3-77.6-73.3-77.9 AUEC (%*h) 1873-596 -6-788 31 43 55 48. (.-839.8) (336.-488.) (48.-624.) (36.-648.6).82.3219

D arameter ooled lacebo mg/kg N=5 mg/kg IgG4 mg/kg a ANOVA (p-value) Tukey s test b Emax (%) -8.81-66.6-58.1-62.3 AUEC (%*h) 9895-62 -474-563 277. (.-648.1) 576. (48-696.) 576. (528.-648.2) N, number of subjects. a For the regimen at the dose mg/kg, only the data from the Cohort are summarized in this table 564. (36.-648.6).4514 b Tukey s test: means are sorted in descending order, black: doses statistically different, gray: doses not statistically different; Kruskal-Wallis test for temax 11

Supplementary Table 4: Demographic Data and Baseline Characteristics SAD art arameter Age, years Median (range) Height, cm Median (range) Weight, kg Median (range) BMI, kg/m 2 Median (range) lacebo N= 39.5 (22-51) 176. (157.-189.) 73.6 (54.8-98.6) 23.85 (19.7-3.4 * ) mg/kg 46.5 (39-5) 18.15 (155.2-186.) 77.3 (55.8-87.6) 23.85 (21.7-26.9) mg/kg 44. (36-51) 178.5 (163.-185.) 74. (54.8-81.2) 23. (2.6-24.3) mg/kg 51.5 (5-53) 171.95 (165.5-178.) 8.9 (78.2-8) 26.95 (.4-29.9) mg/kg 5. (35-55) 182.5 (165.5-19) 75. (72.8-86.8) 23.55 (21.5-26.6) 5 mg/kg 44.5 (4-54) 177.5 (173.-184.) 76.7 (62.8-87.) 24.3 (21.-.7) All subjects N=3 46.5 (22-55) 177.5 (155.2-19) 75.2 (54.8-98.6) 24. (19.7-3.4) Race, n (%) White () 4 () 4 () 4 () 4 () 4 () 3 () Ethnicity, n (%) Not Hispanic or Latino () 4 () 4 () 4 () 4 () 4 () 3 () Gender, n (%) Female Male 3 (3.) 7 (7.) 1 (.) 3 (75.) 4 () N=number of subjects; n=number of subjects with that observation * The BMI of 3.4 kg/m 2 was determined at Day -1. The BMI at screening for this subject was 29.6 kg/m 2. 4 () 4 () 4 () 4 (13.3) 26 (86.7) 12

Supplementary Table 5: Demographic Data and Baseline Characteristics MAD art ( regimen) arameter lacebo N=2 mg/kg () All subjects N=8 Age, years Median (range) 34.5 (3-39) 45.5 (18-53) 4 (18-53) Height, cm Median (range) 18.45 (177.5-183.4) 172.6 (165.8-187.) 175.35 (165.8-187.) Weight, kg Median (range) 82.2 (68.2-96.2) 76.9 (65.-84.4) 76.9 (65.-96.2) BMI, kg/m 2 Median (range). (21.6-28.6) 24.8 (21.7-27.9) 24.8 (21.6-28.6) Race, n (%) Asian White Ethnicity, n (%) Hispanic or Latino Not Hispanic or Latino 2 () 2 () 2 (33.3) 4 (66.7) 1 (16.7) 5 (83.3) 2 (.) 6 (75.) 1 (12.5) 7 (87.5) Gender, n (%) Male 2 () 6 () 8 () N=number of subjects; n=number of subjects with that observation 13

Supplementary Table 6: Demographic Data and Baseline Characteristics MAD art ( regimen) arameter lacebo mg/kg (Cohort 8) * mg/kg (Cohort 9) mg/kg (Cohort ) All subjects N=24 Age, years Median (range) 38.5 (22-53) 48.5 (4-55) 47. (38-53) 44.5 (33-55) 46.5 (22-55) Height, cm Median (range) 185 (177.-192.8) 179. (169.-183.6) 178.75 (168.4-182.8) 178.35 (17.1-183.) 179.3 (168.4-192.8) Weight, kg Median (range) 89. (66.6-97.) 85.4 (6-93.) 79. (67.2-93.4) 77.35 (73.-85.6) 82.5 (6-97.) BMI, kg/m 2 Median (range) 26.2 (21.3-28.9) 26.9 (21.7-29.7) 26.15 (23.2-29.) 24.5 (23.8-27.1).85 (21.3-29.7) Race, n (%) Asian Black or African American White Ethnicity, n (%) Not reported ** Not Hispanic or Latino 6 () 6 () 6 () 6 () 2 (33.3) 4 (66.7) 1 5 () 1 (16.7) 5 (83.3) 6 () 2 (8.3) 1 (4.2) 21 (87.5) 1 23 () Gender, n (%) Male 6 () 6 () 6 () 6 () 24 () N=number of subjects; n=number of subjects with that observation * Subjects in cohort 8 were dosed with either 1 dose (n=1 with placebo and n=3 with ) or 2 doses (n=1 with placebo and n=3 with ) only. ** 'Not reported' values were excluded from the denominator for the percentage calculation. 14

15

2024 © healthdocbox.com Privacy Policy | Terms of Service | Feedback